IDO, a promising target for anti-cancer therapy, is expressed by tumor cells and catalyzes the initial and rate-limiting step of the kynurenine pathway, which leads to the production of kynurenine metabolites and tryptophan depletion. Here, IDO1 is linked to cancer.